MedTrace Logo

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma

NCT00113204 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2008-05-20

No results posted yet for this study

Summary

This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in patients with relapsed and/or relapsed, refractory multiple myeloma. This study will examine how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will also evaluate potential anti-tumor activity of IPI-504.

Conditions

Interventions

DRUG

IPI-504

Sponsors & Collaborators

  • Infinity Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Sundar Jagannath, MD · St. Vincent's Comprehensive Cancer Center

  • David S. Siegel, MD; Ph.D · Hackensack Meridian Health

  • Ivan Borrello, MD · Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center

  • Paul Richardson, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00113204 on ClinicalTrials.gov